Evidence map›Paper›PMID 22521247›Full record

ArticleThe Journal of allergy and clinical immunology2012

Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways.

Victoria J Philbin, David J Dowling, Leighanne C Gallington, Guadalupe Cortés, Zhen Tan, Eugénie E Suter, Kevin W Chi, Ariel Shuckett, Liat Stoler-Barak, Mark Tomai and 3 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 121 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Myeloid TLR2 signaling amplifies immunopathology in influenza-infected murine neonates.American journal of respiratory cell and molecular biology · 2026
    Article
  6. Article
  7. Review
  8. Toll-like receptor agonists as cancer vaccine adjuvants.Human vaccines & immunotherapeutics · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Precision Vaccine Adjuvants for Older Adults: A Scoping Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Victoria J PhilbinDepartment of Medicine, Division of Infectious Diseases, Children's Hospital Boston, Boston, Mass; Harvard Medical School, Boston, MA 02115, USA.
David J Dowling
Leighanne C Gallington
Guadalupe Cortés
Zhen Tan
Eugénie E Suter
Kevin W Chi
Ariel Shuckett
Liat Stoler-Barak
Mark Tomai
Richard L Miller
Keith Mansfield
Ofer Levy
Boston Children's Hospital · USHarvard University · US3M (United States) · USShanghai Jiao Tong University · CN

Funding

Adenosine Shapes Neonatal Toll-like Receptor FunctionR01AI067353 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2006 to 2010
$2.1M
NIAID NIH HHS 3R01AI067353-05S1NIAID NIH HHS R01 AI067353NIAID NIH HHS R01 AI067353-01A1
6 · The paper itself

Abstract

backgroundNewborns have frequent infections and manifest impaired vaccine responses, motivating a search for neonatal vaccine adjuvants. Alum is a neonatal adjuvant but might confer a T(H)2 bias. Toll-like receptor (TLR) agonists are candidate adjuvants, but human neonatal cord blood monocytes demonstrate impaired T(H)1-polarizing responses to many TLR agonists caused by plasma adenosine acting through cyclic AMP. TLR8 agonists, including imidazoquinolines (IMQs), such as the small synthetic 3M-002, induce adult-level TNF from neonatal monocytes, but the scope and mechanisms of IMQ-induced activation of neonatal monocytes and monocyte-derived dendritic cells (MoDCs) have not been reported.

objectiveWe sought to characterize IMQ-induced activation of neonatal monocytes and MoDCs.

methodsNeonatal cord and adult peripheral blood monocytes and MoDCs were cultured in autologous plasma; levels of alum- and TLR agonist-induced cytokines and costimulatory molecules were measured. TLR8 and inflammasome function were assayed by using small interfering RNA and Western blotting/caspase-1 inhibitory peptide, respectively. The ontogeny of TLR8 agonist-induced cytokine responses was defined in rhesus macaque whole blood ex vivo.

resultsIMQs were more potent and effective than alum at inducing TNF and IL-1β from monocytes. 3M-002 induced robust TLR pathway transcriptome activation and T(H)1-polarizing cytokine production in neonatal and adult monocytes and MoDCs, signaling through TLR8 in an adenosine/cyclic AMP-refractory manner. Newborn MoDCs displayed impaired LPS/ATP-induced caspase-1-mediated IL-1β production but robust 3M-002-induced caspase-1-mediated inflammasome activation independent of exogenous ATP. TLR8 IMQs induced robust TNF and IL-1β in whole blood of rhesus macaques at birth and infancy.

conclusionsIMQ TLR8 agonists engage adenosine-refractory TLR8 and inflammasome pathways to induce robust monocyte and MoDC activation and represent promising neonatal adjuvants.

Indexed as

AdenosineAdjuvants, ImmunologicAdultAlum CompoundsAnimalsCaspase 1CytokinesDendritic CellsHumansImidazolesInfant, NewbornMacaca mulattaMonocytesQuinolinesToll-Like Receptor 83M 002AdenosineAdjuvants, ImmunologicAlum Compoundsaluminum sulfateCaspase 1CytokinesImidazolesquinolineQuinolinesTLR8 protein, humanToll-Like Receptor 8

Identifiers

PMID22521247
PMCPMC3387351
OpenAlexW2115541182

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.